Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03932864 · ClinicalTrials.gov registry record · Phase 1
Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor
A Phase 1 study, sponsored by Ensoma.
- Completed
- Registry status
- Phase 1
- Development phase
- 107
- Enrollment target
NCT03932864 is a Phase 1 study that has completed, run by Ensoma. The registered enrollment target is 107 participants.
The verdict
NCT03932864, a Phase 1 study, has completed, sponsored by Ensoma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 107 participants
- Enrollment target
Study Summary
To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MGTA-145 in healthy volunteers as a single agent and in combination with plerixafor.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL MGTA-145
- BIOLOGICAL plerixafor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2019-04-22 |
| Est. Completion | 2020-02-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03932864
The ClinicalTrials.gov registry entry for NCT03932864 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ensoma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03932864 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03932864 about?
NCT03932864 is a clinical study titled "Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor". To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MGTA-145 in healthy volunteers as a single agent and in combination with plerixafor.
What is the current status of trial NCT03932864?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 107 participants. The study started on 2019-04-22. Estimated completion is 2020-02-25.
What interventions are being tested in trial NCT03932864?
The interventions under investigation include: Placebo (BIOLOGICAL), MGTA-145 (BIOLOGICAL), plerixafor (BIOLOGICAL).
Who is sponsoring clinical trial NCT03932864?
This trial is sponsored by Ensoma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.